Interleukin-1 receptor antagonist as therapy for inflammatory disorders

Expert Opinion on Biological Therapy

Volumn 1, Issue 2, 2001, Pages 301-308

  Freeman, Bradley D ^a   Buchman, Timothy G ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

IL 1; Il 1 receptor antagonist; rheumatoid arthritis; sepsis; septic shock

Indexed keywords

IL1RN PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SIALOGLYCOPROTEIN;

CLINICAL TRIAL; DRUG ANTAGONISM; HUMAN; IMMUNOLOGY; INFLAMMATION; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; TREATMENT OUTCOME;

ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; HUMANS; INFLAMMATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; RECEPTORS, INTERLEUKIN-1; SEPSIS; SIALOGLYCOPROTEINS; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 85078372698     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. KLIPPELJH: Biologic therapy for rheumatoid arthritis. ff. Engl.J. Mod. (2000) 343:16-10-1641.
2. PRESENT DH, RUTGEERTS P, TARGAN S et al: Infliximab for the treatment of fistulas in patients with Crohn's disease. Ar. Engl.J. Med. (1999) 340:1398-405.
3. NATANSON C, HUFFMAN \VD, SUFFREDINI AF, EICHACKER PQ, DANNER RL: Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann. Intern. Mod. (1994) 120:771-83. A review of the role of cytokines, both mechanistically and as potential targets in sepsis.
4. ZENIF, FREEMAN BD, NATANSON C: Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crtt. Care Med. (1997) 25:1095-100.
5. FREEMAN B, NATANSON C: Anti-inflammatory therapies in sepsis and septic shock. Exp. Opin. Invest. Drags (2000) 9:1651-63. Comprehensive review of clinical studies of anti-inflammatory therapies in sepsis.
6. BATHON JM, MARTIN RW, FLEISCHMANN RM et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. K. Engl.J. Med. (2000) 343:1586-93. Comprehensive review of clinical studies of anti-inflammatory therapies in sepsis.
7. LIPSKY PE, VAN DER HEIJDE DMFM, ST. CLAIR EW et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. N. Engt. J. Med. (2000) 343:1594-602.
8. DINARELLO CA: Interleukin-1: a pro-inflammatory cytokine. In: Inflammation: Basic Principles and Clinical Conviâtes (Edition 3). Gallin JI, Snyderman R (Eds.), Philadelphia: Lippincott Williams £Wilkins (1999) :443-462. Comprehensive review of biology and the role of IL-1 in disease.
9. DINARELLO C: The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N. Engl.J. Med. (2000) 343:732-34. Comprehensive review of biology' and the role of IL-1 in disease.
10. DAYER JM: Chronic inflammatory jouit diseases: natural inhibitors of interleukin 1 and tumor necrosis factor./ Rbeumatol. (1991) 27(Suppl.):71-75.
11. PRIEUR AM, KAUFMAN MT, GRISCELLI C, DAYER JM: Specific interleukin-1 inhibitor in serum and urine of children with systemic juvenile chronic arthritis. lancet WS7) 2:1240-1242.
12. AREND NVP: Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. J. Clin. Iinvst. (2001) 88:1445-1451.
13. FISCHER E, MARANO MA, VANZEE KJ: Interleukin-1 receptor blockade improves survival and hemodynamic performance in£ coll septic shock, but fails to alter host response to sublethal endotoxemia.J. Clin. Invest. (1992) 89:1551-1557.
14. AIURA K, GELFAND JA, BURKEJF: Interleukln-l receptor antagonist prevents Stapbylococcus epidermis induced hypotension and reduces circulating levels of tumor necrosis factor and EH in rabbits. Infec. Immun. (1993) 61:3342-3350.
15. FISCHER E, VANZEE KJ, MARANO MA: Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease. Blood (1992) 79:2196-2199.
16. GRANOWITZ EV, PORAT R, MIER JW et al: Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine (1992) 4:252-260.
17. FISHER CJ, SLOTMAN GJ, OPAL SM et al.: Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit. CarcMed. (1994) 22:1-21.
18. FISHER CJ, DHAINAUT JF, OPAL SM et al.: Recombinant human Interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome.J. Am. Mcd. Assoc. (1994) 271:1836-1843.
19. OPAL SM, FISHER CJ, DHAINAUT JF: Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a Phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit. Care Mod. (1997) 25:1115-1124.
20. CAMPION GV, LEBSACK ME, LOOKABAUGH J, GORDON G, CATALANO M: Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum. (1996) 39:1092-1110.
21. BRESNIHAN B, ALVARO-GRACIA JM, COBBY M et al.: Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. (1998) 41:2196-2204.
22. OHLSSON K, BJÖRK, BERGENFELDT M, HAGEMAN R, THOMPSON RC: Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. AVtfun?(1990) 348:550-552.
23. WAKABAYASHI G, GELFAND JA, BURKE JF, THOMPSON RC, DINARELLO ÇA: A specific receptor antagonist for Interleukin-1 prevents Escberlcbla coli-induced shock in rabbits. FASEBJ. (1991) 5:338-343.
24. GRANONVrrZ EV, SANTOS AA, POUTSIAICA DD: Production of interleukin-1 receptor antagonist during experimental endotoxemia. Lancet (1991) 338:1423-1424.
25. FREEMAN BD, NATANSON C: Clinical trials in sepsis and septic shock. Curr. Opin. Crit. Care(1995) 1:349-57.
26. FREEMAN BD, EICHACKER PQ. NATANSON C: The role of inflammation in sepsis and septic shock: a nicta-analysis of both clinical and pre-clinical trials of anti-inflammatory therapies. In: Inflammation: Basic Principles and Clinical Correlates (Edition 3). Gallin J, Snyderman R (Eds.), Philadelphia: Lippincott Williams & Wilkins (1999): 965-976.
27. QUEZADO ZMN, BANKS SM, NATANSON C: New strategies for combating sepsis: the magic bullets missed the mark.but the search continues. Trends Biotech. (1995) 13:56-63.
28. NATANSON C, ESPOSITO C, BANKS S: The siren's song of confirmatory sepsis trials: selection bias and sampling errors. Crit. Care Med. (1998) 26:1927-1931.
29. SEVRANSKY JE, NATANSON C: Published clinical trials In sepsis: an update. Sepsis (.1999) 3:11-19.
30. DEP1ETRO MR, NATANSON C: Sepsis trials: what have we learned? Clin. Pulmonary Med. (1999) 6:367-377.
31. LIPSKY PE: Rheumatoid arthritis. In: Hanison's Principles of Internal Medicine (Edition 12). Wilson JD, Braunwald E, IsselbacherKJ étal. (Eds.). McGraw-Hill, Inc., St. Louis (199D:1437-1442.
32. CRONSTEIN BN: Second Une Antirheumatic Drugs. In: Inflammation: Basic Principles and Clinical Correlates (Edition 3). Gallin J, Snyderman R (Eds.), Philadelphia: Lippincott Williams &- Wilkins (2000): 1227-1238.
33. BRESN1HANB: Treatment of rheumatoid arthritis with interleukin-1 receptor antagonist. Ann. Rbciim. Dis. (1999) 58:196-198. This excellent article is a comprehensive review of the role of IL-1 in rheumatoid arthritis and the potential utility of IL-lra in its treatment.
34. GOTO M, FUJISAWA M, YAMADA A, OKABE T, TAKAKU F, SASANO M: Spontaneous release of angiotensin converting enzyme and interleukiii-lb from peripheral blood monocytes from patients -with rheumatoid arthritis under a serum free condition. Ann. Rheum. Dis. (1990) 49:172-176.
35. KAHLE P, SAAL JG, SCHAUDT K, ZACHER J, FRITZ P, PAWELE G: Determination of cytokines in synovial fluids: correlation with diagnosis and histomorphological characteristics of synovia! tissue. Ann. Khctim. Dis. (1992) 51:731-734.
36. YANNI G, WHELAN A, FEIGHERY C, QUINLAN W, SYMONS J, DUFF G: Contrasting levels of in vitro cytokine production by rheumatoid synovial tissues demonstrating different patters of mononuclear cell infiltration. Clin. £xp. Immunol. (1993) 93:387-395.
37. CHANDRASEKHAR S, HARVEY AK,HRUBEY PS, BENDELE AM: Arthritis produced by interleukin-1 injection is dependent on the site and frequency of intra-articular injection. Clin. Immunol. Immunopatb. (2000) 55:382-94.
38. HORAI R, SAIJO S, TANIOKA H et al.: Development of chronic inflammatory arthropathy resembling arthritis in Interleukin-1 receptor antagonist deficient mice./ Exp. Med. (2000) 191:313-320.
39. JOOSTEN LS, HELSEN MM, VAN DE LOO FA, VAN DEN BERG WB: Anti-cytokine treatment of established Type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF-a, anti-IH a/b and IL-lra. Arthritis Rheum. (1996) 39:797-809.
40. BAKKER AC, JOOSTEN LA, ARNTZ OJ et ah Prevention of murinc collagen-induced arthritis in the knee and ipsilateral paw by local expression of human IL-lra protein in the knee. Arthritis Rheum. (1997) 40:893-900.
41. JIANG Y, GENANT HK, WATT I et al.: A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum. (2000) 34:1001-1009.
42. MIRA JP, CAR1OU A, GRAIX F et ah Association of TNF2, a TNF promoter polymorphism, with septic shock susceptibility and mortality - a multicenter study. J. Amer. Mcd. Assoc. (1999) 282(6):56l-568.
43. FISHMAN D, FAULDS G, JEFFREY R et ah The effect of novel polymorphisms in the Interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels and an association with systemic-onset juvenile chronic arthritis./ Clin. Invest. (2000) 102:1369-1376.